[
  {
    "path": "hema/11-25-2022/",
    "title": "Fri Nov 25 2022",
    "description": "86 articles - From Friday Nov 18 2022 to Friday Nov 25 2022",
    "author": [],
    "date": "2022-11-25",
    "categories": [],
    "contents": "\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nparm_toc.knith1 {font-size: 34px;}\r\n       h1.title {font-size: 38px;}\r\n       h2 {font-size: 30px;}\r\n       h3 {font-size: 24px;}\r\n       h4 {font-size: 18px;}\r\n       h5 {font-size: 16px;}\r\n       h6 {font-size: 12px;}\r\n       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}\r\n       pre:not([class]) { background-color: white }\r\n  code{white-space: pre-wrap;}\r\n  span.smallcaps{font-variant: small-caps;}\r\n  span.underline{text-decoration: underline;}\r\n  div.column{display: inline-block; vertical-align: top; width: 50%;}\r\n  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}\r\n  ul.task-list{list-style: none;}\r\n    code{white-space: pre;}\r\nif (window.hljs) {\r\n  hljs.configure({languages: []});\r\n  hljs.initHighlightingOnLoad();\r\n  if (document.readyState && document.readyState === \"complete\") {\r\n    window.setTimeout(function() { hljs.initHighlighting(); }, 0);\r\n  }\r\n}\r\n\r\n.main-container {\r\n  max-width: 940px;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n}\r\nimg {\r\n  max-width:100%;\r\n}\r\n.tabbed-pane {\r\n  padding-top: 12px;\r\n}\r\n.html-widget {\r\n  margin-bottom: 20px;\r\n}\r\nbutton.code-folding-btn:focus {\r\n  outline: none;\r\n}\r\nsummary {\r\n  display: list-item;\r\n}\r\npre code {\r\n  padding: 0;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs {\r\n  display: inline-table;\r\n  max-height: 500px;\r\n  min-height: 44px;\r\n  overflow-y: auto;\r\n  border: 1px solid #ddd;\r\n  border-radius: 4px;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {\r\n  content: \"<U+E258>\";\r\n  border: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active {\r\n  display: block;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li > a,\r\n.tabset-dropdown > .nav-tabs > li > a:focus,\r\n.tabset-dropdown > .nav-tabs > li > a:hover {\r\n  border: none;\r\n  display: inline-block;\r\n  border-radius: 4px;\r\n  background-color: transparent;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li {\r\n  display: block;\r\n  float: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li {\r\n  display: none;\r\n}\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nGuidelines\r\nMeta-analysis\r\nOriginal articles\r\nReviews&Editorials\r\nMiscellaneous\r\nLetters&Replies\r\n\r\n\r\n\r\n$(function () {\r\n          $('#goTop').goTop({\"container\":\"\",\"appear\":200,\"scrolltime\":800,\"src\":\"fas fa-chevron-up\",\"width\":45,\"place\":\"left\",\"color\":\"\",\"fadein\":500,\"fadeout\":500,\"opacity\":0.5,\"marginX\":2,\"marginY\":2,\"zIndex\":9});\r\n         });\r\nGuidelines\r\nGuidelines and related publications, position statements, white papers, technical reviews, consensus statements, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#kqoloodiuu .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#kqoloodiuu .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#kqoloodiuu .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#kqoloodiuu .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#kqoloodiuu .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#kqoloodiuu .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#kqoloodiuu .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#kqoloodiuu .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#kqoloodiuu .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#kqoloodiuu .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#kqoloodiuu .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#kqoloodiuu .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#kqoloodiuu .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#kqoloodiuu .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#kqoloodiuu .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#kqoloodiuu .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#kqoloodiuu .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#kqoloodiuu .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#kqoloodiuu .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#kqoloodiuu .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#kqoloodiuu .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#kqoloodiuu .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#kqoloodiuu .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#kqoloodiuu .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#kqoloodiuu .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#kqoloodiuu .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#kqoloodiuu .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#kqoloodiuu .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#kqoloodiuu .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#kqoloodiuu .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#kqoloodiuu .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#kqoloodiuu .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#kqoloodiuu .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#kqoloodiuu .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#kqoloodiuu .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    \r\n\r\n\r\nMeta-analysis\r\nmeta-analyses and systematic reviews\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#lyrenavhvp .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#lyrenavhvp .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lyrenavhvp .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#lyrenavhvp .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#lyrenavhvp .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#lyrenavhvp .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lyrenavhvp .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#lyrenavhvp .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#lyrenavhvp .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#lyrenavhvp .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#lyrenavhvp .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#lyrenavhvp .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#lyrenavhvp .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#lyrenavhvp .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#lyrenavhvp .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#lyrenavhvp .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#lyrenavhvp .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#lyrenavhvp .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#lyrenavhvp .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#lyrenavhvp .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#lyrenavhvp .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#lyrenavhvp .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#lyrenavhvp .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#lyrenavhvp .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lyrenavhvp .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#lyrenavhvp .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lyrenavhvp .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#lyrenavhvp .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#lyrenavhvp .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#lyrenavhvp .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#lyrenavhvp .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#lyrenavhvp .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#lyrenavhvp .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#lyrenavhvp .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#lyrenavhvp .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    \r\n\r\n\r\nOriginal articles\r\nRCT, clinical trials, retrospective studies, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#tmobgcetcm .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#tmobgcetcm .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#tmobgcetcm .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#tmobgcetcm .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#tmobgcetcm .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#tmobgcetcm .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#tmobgcetcm .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#tmobgcetcm .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#tmobgcetcm .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#tmobgcetcm .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#tmobgcetcm .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#tmobgcetcm .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#tmobgcetcm .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#tmobgcetcm .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#tmobgcetcm .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#tmobgcetcm .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#tmobgcetcm .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#tmobgcetcm .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#tmobgcetcm .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#tmobgcetcm .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#tmobgcetcm .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#tmobgcetcm .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#tmobgcetcm .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#tmobgcetcm .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#tmobgcetcm .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#tmobgcetcm .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#tmobgcetcm .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#tmobgcetcm .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#tmobgcetcm .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#tmobgcetcm .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#tmobgcetcm .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#tmobgcetcm .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#tmobgcetcm .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#tmobgcetcm .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#tmobgcetcm .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Ann Oncol\r\n    Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer: a pooled analysis.\r\n Long-term survival benefit and durable response with nivolumab plus ipilimumab in this large patient population further support this first-line treatment option for advanced NSCLC.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMolecular and clinical diversity in primary central nervous system lymphoma.\r\nThe integration of genome-wide data from multi-omics data revealed four molecular patterns in PCNSL with a distinctive prognostic impact that provides a basis for future clinical stratification and subtype-based targeted interventions.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNeoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: A prospective multi-center randomized clinical trial.\r\nNCRT followed by MIE was not associated with significantly better overall survival than nCT among patients with cT3-4aN0-1M0 ESCC. The results underscore the pending issue of the best strategy of neoadjuvant therapy for locally advanced bulky ESCC.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    A phase 2 study of Interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract.\r\nThis work demonstrates a potential approach for combining immunosuppression with tissue-supportive strategies to enhance recovery of damaged mucosa and promote microbial health in patients with gastrointestinal GVHD. This work was supported by funding from Evive Biotech., The Society of Memorial Sloan Kettering Cancer Center, and the National Institutes of Health.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAllogeneic natural killer cell therapy.\r\nBasic advances in NK cells biology and cellular engineering have led to new translational strategies to block inhibition, enhance and broaden target cell recognition, optimize functional persistence, and provide stealth from patients' immunity. This review details NK cell biology, as well as NK cell product manufacturing, engineering, and combination therapies explored in the clinic leading to the next generation of potent, off-the-shelf cellular therapies for blood cancers.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDetermining venous thromboembolism risk in patients with adult-type diffuse glioma.\r\nThese ten variables were used to create a web-based VTE prediction tool which was validated in two separate cohorts of adult-type diffuse glioma patients from other institutions. This study extends our understanding of the VTE landscape in these tumors, and provides evidence-based guidance for clinicians to mitigate VTE risk in glioma patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nFLT3ITD drives context-specific changes in cell identity and variable interferon dependence during AML initiation.\r\nThus, common AML driver mutations, such as FLT3ITD, can co-opt different mechanisms of transformation in different genetic contexts. Furthermore, pediatric-biased NUP98 fusions convey actionable interferon dependence.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHow I treat Elderly Patients with DLBCL in the frontline setting.\r\nFurther progress can be expected from non-chemotherapy based therapies, such as bispecific antibodies, antibody-drug conjugates and immunomodulatory agents. This article provides an overview of first line treatment in elderly patients with DLBCL and our approach to the management of these challenging patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHow we diagnose and treat acute graft-versus-host disease after solid organ transplantation.\r\nFor GVHD involving the marrow we initiate an allogeneic hematopoietic cell donor search early. In this article, we describe three cases of GVHD after SOT, outline our approach to diagnosis and management, and then provide analysis of the three instructive cases.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHow We Use Risk Factors for Success or Failure of CD19 CAR T-cells to Guide Management of Children/AYA with B-cell ALL.\r\nWe include data from both prospective and recent large retrospective studies that offer insight into understanding when risks of CAR T-cell therapy failure are high and offer perspectives suggesting when consolidative hematopoietic cell transplantation (HCT) or experimental CAR T-cell and/or alternative immunotherapy should be considered. We also propose areas where prospective trials addressing optimal use of CAR T-cell therapy are needed.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nKruppel-like factor 1-GATA1 fusion protein improves the sickle cell disease phenotype in mice both inÂ vitro and inÂ vivo.\r\nTransplantation of highly purified SCD mouse HSCs expressing KLF1-GATA1 fusion protein into SCD mice lessened the severity of the anemia, reduced the sickling of red blood cells, improved SCD-related pathological alterations in spleen, kidney, and liver, and restored urine-concentrating ability in recipient mice. Taken together, these results indicate that the use of KLF1-GATA1 fusion constructs may represent a new gene therapy approach for hemoglobinopathies.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNorth American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need.\r\nThis group of experts includes a multi-disciplinary panel of hematologists/oncologists, hematopoietic stem cell transplant physicians, pathologists, dermatologists, and pediatric oncologists, and was tasked with defining the current standard of care in the field and identifying the most important research questions and future directions in BPDCN. The position findings of the NABC's inaugural meetings are presented herein.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNovel variants in GALE cause syndromic macrothrombocytopenia by disrupting glycosylation and thrombopoiesis.\r\nAltered distribution of filamin A and actin and delocalization of the von Willebrand Factor were also demonstrated. Overall, this study expands our knowledge of GALE-related thrombocytopenia and emphasized the critical role of GALE in the physiological glycosylation of key proteins involved in platelet production and function.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRandomized, Placebo-Controlled, Phase 3 Trial of PI3Kd Inhibitor Leniolisib for Activated PI3Kd Syndrome.\r\n(Funded by DIR/NIAID, Novartis, and Pharming Group, NV;  ClinicalTrials. gov identifier: NCT02435173.).\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    Anti-HK antibody inhibits the plasma contact system by blocking prekallikrein and factor XI activation in vivo.\r\nMoreover, 3E8 blocked PKa binding to HK and dose-dependently inhibited PKa cleavage of HK. Our results reveal a novel strategy to inhibit contact system activation in vivo, which may provide an effective method to treat human diseases involving contact system dysregulation.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAnti-leukemic properties of the kinase inhibitor OTSSP167 in T cell acute lymphoblastic leukemia.\r\nOTSSP167 exhibited synergistic interactions when combined with dexamethasone, L-asparaginase, vincristine, and etoposide. Our findings reveal novel anti-leukemic properties of OTSSP167 in T-ALL and support the use of OTSSP167 as an adjuvant drug to increase treatment response and reduce relapses in pediatric T-ALL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCoping in Caregivers of Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation.\r\nOur findings suggest that coping is related to distress and QOL among caregivers of HSCT recipients even pre-transplant. Hence, caregivers of patients with hematologic malignancies undergoing HSCT may benefit from resources that facilitate adaptive coping with the demands of caregiving.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDynamin-2 deficiency causes age- and sex-dependent neutropenia and myelodysplasia in mice.\r\nIn summary, female mice with bone marrow Dnm2 haploinsufficiency developed neutropenia as they aged with decreased granulocyte progenitor production and migration defects. Our studies indicate a potential mechanism for the development of chronic idiopathic neutropenia, a disease that predominantly presents in middle-aged women.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEfficacy, Safety, and Molecular Response Predictors of Oral Ixazomib and Short-Course Rituximab in Untreated iNHL.\r\nIxazomib demonstrated efficacy alone and with short course rituximab in untreated iNHL while exhibiting favorable toxicity, convenience, and retention of B-cell immune response. This trial is registered at as NCT02339922.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHost metabolome predicts the severity and onset of acute toxicities induced by CAR T-cell therapy.\r\nLower concentration of the amino acid hydroxyproline was associated with higher grade and faster onset of ICANS, whereas low glutamine was negatively correlated with faster development of ICANS. Overall, our data indicate that the pre-treatment host metabolome has biomarker potential in determining the risk of clinically significant CRS and ICANS, and may be useful in risk stratification of patients prior to anti-CD19 CAR T-cell therapy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLevofloxacin prophylaxis vs no prophylaxis in neutropenic patients within an endemic country for carbapenem-resistant GNB.\r\nComparing antimicrobial resistance among Gram-negative bacteria in the setting of allo-HSCT, in the group without FQ-P a significantly higher proportion of pathogens was susceptible to piperacillin/tazobactam (71% versus 30%, p=0.026), FQ (49% versus 10%, p=0.03) and carbapenems (95% versus 50%, p=0.001). FQ-P discontinuation increased Gram-negative bacteria PE-BSI, but it did not impact IRM, both in ASCT and allo-HSCT setting;  importantly, it concurred to decrease significantly antimicrobial resistance in Gram-negative bacteria.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nOpen-Label, Pilot Study of Romiplostim for Thrombocytopenia After Autologous Hematopoietic Cell Transplantation.\r\nOnly 1 adverse event was deemed possibly attributable to romiplostim, a low-risk pulmonary embolism in a patient with multiple myeloma. In conclusion, romiplostim showed promising activity and safety after autoHCT, but the improvement in platelet counts occurred later than the goal of shortening the duration and depth of the platelet nadir.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nOptical Genome Mapping in Acute Myeloid Leukemia: A Multicenter Evaluation.\r\nThe results from this multi-institutional study indicate that OGM effectively recovers clinically relevant SVs and CNVs found by standard of care methods and reveals additional SVs not reported. Furthermore, OGM minimizes the need for labor-intensive multiple cytogenetic tests while concomitantly maximizing diagnostic detection through a standardized workflow.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPeripheral Blood Monocyte Count is a Dynamic Prognostic Biomarker in Multiple Myeloma.\r\nAbnormal AMC was also associated with inferior OS independent of validated prognostic markers including the international staging system stage ISS Stage, and high lactate dehydrogenase LDH. Our findings provide novel clues for future prospective studies on the functional role of monocytes in multiple myeloma, which could be a readily available metric for risk stratification.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSafety and Immunogenicity of V114, a 15-valent Pneumococcal Conjugate Vaccine, in Children with Sickle Cell Disease (PNEU-SICKLE).\r\nTrial Registration: ClinicalTrials. gov: NCT03731182;  EudraCT: 2018-001152-35.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML.\r\nMechanistically, stimulation of C3AR-expressing cells with C3a, the ligand of C3AR, leads to activation of ERK1/2 and increased survival of AML cells, suggesting that this is an important signaling axis in this subtype of AML. Finally, we show that antibodies directed against C3AR efficiently elicit NK cell-mediated killing of primary AML cells ex vivo, highlighting C3AR as a candidate therapeutic target in NPM1-mutated AML.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTranscriptional reprogramming of infiltrating neutrophils drives lung disease in severe COVID-19 despite low viral load.\r\nIn addition, exacerbated neutrophil production of IL-8, IL-1ÃŸ, IL-6, and CCL3/4, along with elevated levels of neutrophil elastase and myeloperoxidase, were the hallmarks of a transcriptionally active and pathogenic airway neutrophilia. Although our analysis was limited to Black/AA patients and was not designed as a comparative study across different ethnicities, we present an unprecedented in-depth analysis of the immunopathology that leads to ARDS in a well-defined patient population disproportionally affected by severe COVID-19.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nUnderweight children over 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.\r\nUnderweight participants (weight-for-age z-score < -1) had a greater probability of death during follow-up than those not underweight (p=0.043). Underweight status in school-aged children with sickle cell anemia is a previously unrecognized risk factor for early mortality in Nigeria and can be easily applied to screen children at risk for death.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial).\r\nAnd they were 94% vs 87%, and 85% vs 78% in the high-risk patients (P=0.52 and P=0.44, respectively). This study demonstrated that ATRA-ATO had the same efficacy as the ATRA-ATO plus CHT in the treatment of patients with all-risk APL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nValidation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party.\r\nUnivariate and multivariate analyses demonstrated that the presence of plasmacytoma and elevated serum ÃŸ2-microglobulin were significantly associated with OS in primary PCL. In conclusion, the revised criterion of CPCs = 5% in a peripheral blood smear is appropriate for PCL diagnosis.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHaematologica\r\n    IDH mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAnimal models of Diamond-Blackfan anemia: updates and challenges.\r\nIn the past decades, researchers have made significant progress in understanding the pathogenesis of DBA, but it remains unclear how the ubiquitous RP haploinsufficiency causes the erythroid-specific defect in hematopoiesis in DBA patients, and why there is a difference in penetrance and spontaneous remission among individuals who carry identical mutations. In this paper, we provide a comprehensive review of the development of DBA animal models and discuss the future research directions for these important experimental systems.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAxicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nClinical response to dabrafenib and chemotherapy in clonally-related histiocytosis and acute lymphoblastic leukemia.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nClonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCOVID-19 pandemic affects the ability of negative D-dimer to identify venous thromboembolism patients at low risk of recurrence: insights from Apidulcis study.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDiffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL).\r\nClinical characteristics were similar between LO and EO, but LO more frequently received palliation (50% vs 23%: P=0.001) and had worse 2-year overall survival (OS) (48% vs 63%: P=0.001) and 2-year progression-free survival (PFS) (43% vs 56%: P=0.01). Patients receiving anthracycline did better than patients receiving palliation (P.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDisrupting autophagy in FLT3-mutant AML.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDysfunctional subsets of CD39+ T cells, distinct from PD-1+, driven by leukemic extracellular vesicles in myeloid leukemias.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHow different are blood platelets from women or men, young or elderly people?\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHyperactive CREB subpopulations increase during therapy in paediatric B lineage acute lymphoblastic leukaemia.\r\nThe small molecule CREB inhibitor, 666-15, was shown to reduce CREB transcriptional activity and induce apoptosis in ALL PDX cells of varying cytogenetic subtypes in vitro, both in the presence and absence of stromal support. Together, these data suggest that the cAMP signalling pathway may provide an opportunity for MRD-directed therapy for many patients at high risk of relapse.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLandscape of immunoglobulin heavy chain gamma gene class switch recombination in patients with adult T-cell leukemia-lymphoma.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPrevention and management of secondary central nervous system lymphoma.\r\nIn this review we focus on the identification of high-risk patients, prophylaxis strategies and recent treatment approaches for SCNSL. The incorporation of novel agents to immunochemotherapy deserves further study in prospective trials.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTargeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma.\r\nMoreover, telaglenastat showed anti-MCL synergy when combined with ibrutinib or venetoclax in vitro, which was confirmed using an MCL patient-derived xenograft model. Our study provides the first evidence that targeting GLS with telaglenastat, alone or in combination with ibrutinib or venetoclax, is a promising strategy to overcome ibrutinib resistance in MCL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.\r\nCombination immunotherapy in this setting should be further studied in patients with classic Hodgkin lymphoma with further refinement of the regimen to mitigate toxic effects, particularly in high-risk patients in whom more intensive therapy to prevent relapse is warranted. Funding Bristol Myers Squibb, Leukemia and Lymphoma Society, Lymphoma Research Foundation, and National Cancer Institute of the National Institutes of Health.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPonatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.\r\nPatients with newly diagnosed Ph-positive acute lymphoblastic leukaemia could be spared the toxicities associated with chemotherapy and the need for allogeneic haematopoietic stem-cell transplantation in first response. Funding Takeda Oncology and Amgen.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nZanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.\r\nThese results suggest that zanubrutinib, a safe and viable treatment for patients with B-cell malignancies, might fill that unmet need for those who exhibit intolerance to ibrutinib or acalabrutinib. Funding BeiGene.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML).\r\nR132H mutation leads to CTCF hypermethylation, disrupting DNA-looping and insulation of PDGFRA, resulting in PDGFRA upregulation in IDH1-mutant AML. Treatment with dasatinib may offer a novel treatment strategy for IDH1-mutant AML.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nP2X1 enhances leukemogenesis through PBX3-BCAT1 pathways.\r\nThe P2X1 antagonist sufficiently suppressed AML cell proliferation. These results provided a unique perspective on how metabolic niche factor ATP fine-tunes LIC activities, which may benefit the development of strategies for targeting LICs or other cancer stem cells.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTargeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia.\r\nAdditionally, direct promotion of apoptosis with venetoclax, showed substantial synergy with chemotherapy, overcoming resistance mediated by impaired cell cycle arrest. Altogether, we identify defective cell cycle arrest as a clinically relevant contributor to chemoresistance and identify rationally designed therapeutic combinations that enhance response in AML, potentially circumventing chemoresistance.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThromb Haemost\r\n    Assessment of DOAC in GEriatrics (ADAGE study): rivaroxaban/apixaban concentrations and thrombin generation profiles in NVAF very elderly patients.\r\n Our study provides original data in very elderly patients receiving DOAC in real-life setting, showing great inter-individual variability in plasma concentrations and TG parameters. Further research is needed to understand the potential clinical impact of these findings.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAssociation between sports participation, factor VIII levels and bleeding in hemophilia A.\r\nThis analysis showed that FVIII levels were an important determinant of the bleeding hazard, but sports participation was not. This observation most likely reflects the presence of adequate FVIII levels during sports participation in our study. Persons with severe hemophilia A exhibited a higher bleeding hazard at a similar FVIII levels than non-severe, suggesting that the time spent at lower FVIII levels impacts overall bleeding hazard. These data may be used to counsel persons with hemophilia regarding sports participation and the necessity of adequate prophylaxis.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGenetic predisposition of both waist circumference and hip circumference increased the risk of venous thromboembolism.\r\n There is a significant causal relationship between WC/HC and VTE/PE, which is consistent with observational studies. Taking measures to reduce WC/HC of obesity may help reduce the incidence of VTE/PE.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImpact of ABO Blood Group on Thromboembolic and Bleeding Complications in Patients with Left Ventricular Assist Devices.\r\n LVAD patients with blood group O are at an increased bleeding risk , potentially due to lower VWF and FVIII levels.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nObesity and the Risk of Venous Thromboembolism after Major Lower Limb Orthopaedic Surgery: A Literature Review.\r\nHence any increase in dosage may require intensive surveillance for the residual anticoagulant effects and careful balancing of risks and benefits on an individual basis. Our review discusses the basis for increased thrombotic risk in obesity, the evidence supporting dosage recommendations, and the implications of the current guidelines for pharmacological thromboprophylaxis in patients with obesity undergoing lower limb arthroplasty.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRole of GPR56 in platelet activation and arterial thrombosis.\r\nInhibition of the initial response of GPR56 to collagen could significantly inhibit platelet activation and thrombus formation. Our results provide new insights for research into antiplatelet drugs.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSevere left atrial spontaneous echo contrast in non-valvular atrial fibrillation: Clinical characteristics and impact on ischemic risk post-ablation.\r\nHigher BNP, ESR, LAd/LVED were the independent predictors for severe SEC. Severe SEC were associated with higher peri-procedural and long-term ischemic risks. ESR and LAd/LVED, as indicators of hematological and hemodynamic change, seemed helpful in identifying NVAF patients prone to developing severe SEC.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nReviews&Editorials\r\nPlenty of the editorials are available as full text through the publisher website using the provided link\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#fhubmpbsld .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#fhubmpbsld .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fhubmpbsld .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#fhubmpbsld .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#fhubmpbsld .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#fhubmpbsld .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fhubmpbsld .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#fhubmpbsld .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#fhubmpbsld .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#fhubmpbsld .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#fhubmpbsld .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#fhubmpbsld .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#fhubmpbsld .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#fhubmpbsld .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#fhubmpbsld .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#fhubmpbsld .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#fhubmpbsld .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#fhubmpbsld .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#fhubmpbsld .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#fhubmpbsld .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#fhubmpbsld .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#fhubmpbsld .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#fhubmpbsld .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#fhubmpbsld .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fhubmpbsld .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#fhubmpbsld .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fhubmpbsld .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#fhubmpbsld .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#fhubmpbsld .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#fhubmpbsld .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#fhubmpbsld .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#fhubmpbsld .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#fhubmpbsld .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#fhubmpbsld .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#fhubmpbsld .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Bruton tyrosine kinase inhibitors in the management of WaldenstrÃ¶m macroglobulinemia.\r\nAlthough associated with high rates of durable responses, unmet needs with BTK inhibitor therapy include indefinite duration therapy, high cost, scarcity of complete responses, and lower rates and shorter duration of response in patients with CXCR4 mutations. Herein, we review the data supporting the use of covalent BTK inhibitors, selected management issues, clinical trials with covalent BTK inhibitor combination regimens, and up-and-coming non-covalent BTK inhibitors.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    A-two to the rescue.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nA challenging choice: consolidation in Ph+ ALL.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAxi-cel in LBCL: fulfill twoÂ needs with one deed.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBumping CAR T cells up aÂ Notch.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCardiotoxicity in patients treated with acalabrutinib.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGVHD prevention by personalized nutrition.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMechanisms of resistance toÂ venetoclax.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPlatelets: out of shape and misbehaving.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nProtecting the fetus from FNAIT.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Managing WaldenstrÃ¶m's macroglobulinemia with BTK inhibitors.\r\nIn the future, BTKis may be increasingly utilized within combination regimens. Several ongoing trials in WM are investigating the potential for BTKi use in combination with established and novel targeted agents.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nMiscellaneous\r\nmisc publications eg case reports, tools of the trade, images of the month, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#mgyvjmdxge .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#mgyvjmdxge .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#mgyvjmdxge .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#mgyvjmdxge .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#mgyvjmdxge .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#mgyvjmdxge .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#mgyvjmdxge .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#mgyvjmdxge .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#mgyvjmdxge .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#mgyvjmdxge .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#mgyvjmdxge .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#mgyvjmdxge .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#mgyvjmdxge .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#mgyvjmdxge .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#mgyvjmdxge .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#mgyvjmdxge .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#mgyvjmdxge .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#mgyvjmdxge .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#mgyvjmdxge .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#mgyvjmdxge .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#mgyvjmdxge .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#mgyvjmdxge .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#mgyvjmdxge .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#mgyvjmdxge .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#mgyvjmdxge .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#mgyvjmdxge .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#mgyvjmdxge .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#mgyvjmdxge .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#mgyvjmdxge .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#mgyvjmdxge .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#mgyvjmdxge .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#mgyvjmdxge .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#mgyvjmdxge .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#mgyvjmdxge .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#mgyvjmdxge .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Allogeneic transplantation for chronic myeloid leukemia: I'm not dead yet!\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRefractory idiopathic multicentric Castleman disease responsive to sirolimus therapy.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    Allogeneic HCT for Ph+ ALL in CR1 with CMR.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlast phagocytosis.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCollins PJ, Fox CP, George L, etÂ al. Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells. Blood. 2021;137(2):203-215.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHigh frequency of low-count monoclonal B-cell lymphocytosis in hospitalized COVID-19 patients.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMetastatic carcinoma mimicking hemophagocytic lymphohistiocytosis.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    Salvage polatuzumab and allogeneic transplant rescues patients with B-cell lymphoma failing CAR T-cell therapy.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    How does zanubrutinib fare in treatment of B-cell malignancies?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTowards chemotherapy-free treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nLetters&Replies\r\nLetters to the editors and authorsâ€™ replies\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#boyrsfwkav .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#boyrsfwkav .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#boyrsfwkav .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#boyrsfwkav .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#boyrsfwkav .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#boyrsfwkav .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#boyrsfwkav .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#boyrsfwkav .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#boyrsfwkav .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#boyrsfwkav .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#boyrsfwkav .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#boyrsfwkav .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#boyrsfwkav .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#boyrsfwkav .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#boyrsfwkav .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#boyrsfwkav .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#boyrsfwkav .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#boyrsfwkav .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#boyrsfwkav .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#boyrsfwkav .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#boyrsfwkav .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#boyrsfwkav .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#boyrsfwkav .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#boyrsfwkav .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#boyrsfwkav .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#boyrsfwkav .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#boyrsfwkav .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#boyrsfwkav .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#boyrsfwkav .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#boyrsfwkav .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#boyrsfwkav .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#boyrsfwkav .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#boyrsfwkav .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#boyrsfwkav .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#boyrsfwkav .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Fetal Hemoglobin per Erythrocyte (HbF/F-cell) After Gene Therapy for Sickle Cell Anemia.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPost-transplant Cyclophosphamide in Acute Leukemia Patients Receiving more than 5/10 HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation from Related Donors: a Study on behalf of the ALWP of the EBMT.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nReduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe Feasibility of Additional CD19-Targeted Cellular Therapy in Relapsed/Refractory B-ALL with Re-emergence of CD19 Antigen After Prior CD19-negative Relapse.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    SIRPa-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPa signal pathway via blocking the \"don't eat me\" signal and activating the \"eat me\" signal.\r\nFinally, IMM01 demonstrated a favorable safety profile with no human RBC binding activity or hemagglutination induction. IMM01 inhibits the growth of tumor cells by the following three possible mechanisms: (1) directly activating macrophages to phagocytize tumor cells;  (2) activated macrophages degrade phagocytized tumor cells and present tumor antigens to T cells through MHC molecules to activate T cells;  (3) activated macrophages can convert \"cold tumors\" into \"hot tumors\" and increase the infiltration of immune cells through chemotaxis by secreting some cytokines and chemokines.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Should we give oligomonocytic chronic myelomonocytic leukemia a higher prominence in the next WHO Classification of Haematolymphoid Tumors?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n// add bootstrap table styles to pandoc tables\r\nfunction bootstrapStylePandocTables() {\r\n  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');\r\n}\r\n$(document).ready(function () {\r\n  bootstrapStylePandocTables();\r\n});\r\n\r\n\r\n\r\n$(document).ready(function () {\r\n  window.buildTabsets(\"TOC\");\r\n});\r\n\r\n$(document).ready(function () {\r\n  $('.tabset-dropdown > .nav-tabs > li').click(function () {\r\n    $(this).parent().toggleClass('nav-tabs-open');\r\n  });\r\n});\r\n\r\n  (function () {\r\n    var script = document.createElement(\"script\");\r\n    script.type = \"text/javascript\";\r\n    script.src  = \"https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML\";\r\n    document.getElementsByTagName(\"head\")[0].appendChild(script);\r\n  })();\r\n\r\n\r\n\r\n\r\n\r\n",
    "preview": {},
    "last_modified": "2022-11-25T12:28:34-05:00",
    "input_file": {}
  },
  {
    "path": "hema/11-18-2022/",
    "title": "Fri Nov 18 2022",
    "description": "82 articles - From Friday Nov 11 2022 to Friday Nov 18 2022",
    "author": [],
    "date": "2022-11-18",
    "categories": [],
    "contents": "\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nparm_toc.knith1 {font-size: 34px;}\r\n       h1.title {font-size: 38px;}\r\n       h2 {font-size: 30px;}\r\n       h3 {font-size: 24px;}\r\n       h4 {font-size: 18px;}\r\n       h5 {font-size: 16px;}\r\n       h6 {font-size: 12px;}\r\n       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}\r\n       pre:not([class]) { background-color: white }\r\n  code{white-space: pre-wrap;}\r\n  span.smallcaps{font-variant: small-caps;}\r\n  span.underline{text-decoration: underline;}\r\n  div.column{display: inline-block; vertical-align: top; width: 50%;}\r\n  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}\r\n  ul.task-list{list-style: none;}\r\n    code{white-space: pre;}\r\nif (window.hljs) {\r\n  hljs.configure({languages: []});\r\n  hljs.initHighlightingOnLoad();\r\n  if (document.readyState && document.readyState === \"complete\") {\r\n    window.setTimeout(function() { hljs.initHighlighting(); }, 0);\r\n  }\r\n}\r\n\r\n.main-container {\r\n  max-width: 940px;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n}\r\nimg {\r\n  max-width:100%;\r\n}\r\n.tabbed-pane {\r\n  padding-top: 12px;\r\n}\r\n.html-widget {\r\n  margin-bottom: 20px;\r\n}\r\nbutton.code-folding-btn:focus {\r\n  outline: none;\r\n}\r\nsummary {\r\n  display: list-item;\r\n}\r\npre code {\r\n  padding: 0;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs {\r\n  display: inline-table;\r\n  max-height: 500px;\r\n  min-height: 44px;\r\n  overflow-y: auto;\r\n  border: 1px solid #ddd;\r\n  border-radius: 4px;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {\r\n  content: \"<U+E258>\";\r\n  border: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active {\r\n  display: block;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li > a,\r\n.tabset-dropdown > .nav-tabs > li > a:focus,\r\n.tabset-dropdown > .nav-tabs > li > a:hover {\r\n  border: none;\r\n  display: inline-block;\r\n  border-radius: 4px;\r\n  background-color: transparent;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li {\r\n  display: block;\r\n  float: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li {\r\n  display: none;\r\n}\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nGuidelines\r\nMeta-analysis\r\nOriginal articles\r\nReviews&Editorials\r\nMiscellaneous\r\nLetters&Replies\r\n\r\n\r\n\r\n$(function () {\r\n          $('#goTop').goTop({\"container\":\"\",\"appear\":200,\"scrolltime\":800,\"src\":\"fas fa-chevron-up\",\"width\":45,\"place\":\"left\",\"color\":\"\",\"fadein\":500,\"fadeout\":500,\"opacity\":0.5,\"marginX\":2,\"marginY\":2,\"zIndex\":9});\r\n         });\r\nGuidelines\r\nGuidelines and related publications, position statements, white papers, technical reviews, consensus statements, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#rhwdokyegp .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#rhwdokyegp .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#rhwdokyegp .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#rhwdokyegp .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#rhwdokyegp .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#rhwdokyegp .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#rhwdokyegp .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#rhwdokyegp .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#rhwdokyegp .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#rhwdokyegp .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#rhwdokyegp .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#rhwdokyegp .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#rhwdokyegp .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#rhwdokyegp .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#rhwdokyegp .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#rhwdokyegp .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#rhwdokyegp .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#rhwdokyegp .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#rhwdokyegp .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#rhwdokyegp .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#rhwdokyegp .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#rhwdokyegp .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#rhwdokyegp .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#rhwdokyegp .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#rhwdokyegp .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#rhwdokyegp .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#rhwdokyegp .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#rhwdokyegp .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#rhwdokyegp .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#rhwdokyegp .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#rhwdokyegp .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#rhwdokyegp .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#rhwdokyegp .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#rhwdokyegp .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#rhwdokyegp .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Ann Oncol\r\n    Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nMeta-analysis\r\nmeta-analyses and systematic reviews\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#aaicyrsdgm .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#aaicyrsdgm .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#aaicyrsdgm .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#aaicyrsdgm .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#aaicyrsdgm .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#aaicyrsdgm .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#aaicyrsdgm .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#aaicyrsdgm .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#aaicyrsdgm .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#aaicyrsdgm .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#aaicyrsdgm .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#aaicyrsdgm .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#aaicyrsdgm .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#aaicyrsdgm .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#aaicyrsdgm .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#aaicyrsdgm .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#aaicyrsdgm .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#aaicyrsdgm .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#aaicyrsdgm .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#aaicyrsdgm .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#aaicyrsdgm .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#aaicyrsdgm .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#aaicyrsdgm .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#aaicyrsdgm .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#aaicyrsdgm .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#aaicyrsdgm .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#aaicyrsdgm .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#aaicyrsdgm .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#aaicyrsdgm .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#aaicyrsdgm .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#aaicyrsdgm .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#aaicyrsdgm .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#aaicyrsdgm .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#aaicyrsdgm .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#aaicyrsdgm .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Lancet Haematol\r\n    Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis.\r\nFurther investigations are needed to improve understanding on why lenalidomide only promotes SPM in patients with multiple myeloma. Funding None.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nOriginal articles\r\nRCT, clinical trials, retrospective studies, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#zjzynrhnxn .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#zjzynrhnxn .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#zjzynrhnxn .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#zjzynrhnxn .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#zjzynrhnxn .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#zjzynrhnxn .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#zjzynrhnxn .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#zjzynrhnxn .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#zjzynrhnxn .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#zjzynrhnxn .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#zjzynrhnxn .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#zjzynrhnxn .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#zjzynrhnxn .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#zjzynrhnxn .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#zjzynrhnxn .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#zjzynrhnxn .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#zjzynrhnxn .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#zjzynrhnxn .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#zjzynrhnxn .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#zjzynrhnxn .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#zjzynrhnxn .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#zjzynrhnxn .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#zjzynrhnxn .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#zjzynrhnxn .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#zjzynrhnxn .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#zjzynrhnxn .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#zjzynrhnxn .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#zjzynrhnxn .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#zjzynrhnxn .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#zjzynrhnxn .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#zjzynrhnxn .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#zjzynrhnxn .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#zjzynrhnxn .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#zjzynrhnxn .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#zjzynrhnxn .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Blood\r\n    -----NRX-0492 Degrades Wildtype and C481 Mutant BTK and Demonstrates in vivo Activity in CLL Patient Derived Xenografts.\r\nOral bioavailability, >90% degradation of BTK at sub-nanomolar concentrations and sustained pharmacodynamic effects after drug clearance make this class of targeted protein degraders uniquely suitable for clinical translation, in particular as a strategy to overcome BTK inhibitor resistance. Clinical studies testing this approach have been initiated (NCT04830137, NCT05131022).\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nA Novel RIPK1 Inhibitor Reduces GVHD in Mice via a Non-immunosuppressive Mechanism that Restores Intestinal Homeostasis.\r\nFinally, we discover a selective and potent RIPK1 inhibitor (Zharp1-211) that significantly reduces JAK/STAT1-mediated expression of chemokines and MHC class II molecules in IECs, restores intestinal homeostasis and arrests GVHD without compromising the graft-versus-leukemia (GVL) effect. Thus, targeting RIPK1/RIPK3 in IECs represents an effective non-immunosuppressive strategy for GVHD treatment and potentially for other diseases involving GI tract inflammation.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAging drives Tet2+/- clonal hematopoiesis via IL-1 signaling.\r\nIn agreement, IL-1a-treated Tet2+/- HSCs showed increased DNA replication and repair transcriptomic signatures and reduced susceptibility to IL-1a-mediated downregulation of self-renewal genes. Importantly, genetic deletion of IL-1R1 in Tet2+/- HPSC or pharmacological inhibition of IL-1 signaling impaired Tet2+/- clonal expansion, establishing the IL-1 pathway as a relevant and therapeutically targetable driver of Tet2+/- CHIP progression during aging.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBiallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.\r\nIn the multivariate analysis, del(1p32) appeared as a negative prognostic factor;  after adjustment for age and treatment, the risk of progression was 1.3 times higher among patients harboring del(1p32), and the risk of death was 1.9 times higher. At the dawn of risk-adapted treatment strategies, we have confirmed the adverse impact of del(1p32) in MM and the relevance of its assessment at diagnosis.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1.\r\nFurthermore, following BTG1 deletion or expression of BTG1 mutations observed in DLBCL patients, the overactivation of the BCAR1-RAC1 pathway confers increased migration ability in vitro and in vivo. These modifications are targetable with the SRC inhibitor dasatinib, which opens novel therapeutic opportunities in BTG1 mutated DLBCL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEssential thrombocythemia: challenges in clinical practice and future prospects.\r\nIn this review we provide a practical overview of diagnosis and management of ET with a focus upon difficult patient scenarios and some consideration of what comprehensive care might require. Finally, we also discuss newer therapies and how these might be assessed.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nFLT3ITD drives context-specific changes in cell identity and variable interferon dependence during AML initiation. \r\nThus, common AML driver mutations, such as FLT3ITD, can co-opt different mechanisms of transformation in different genetic contexts. Furthermore, pediatric-biased NUP98 fusions convey actionable interferon dependence.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHow we diagnose and treat acute graft-versus-host disease after solid organ transplantation. \r\nFor GVHD involving the marrow we initiate an allogeneic hematopoietic cell donor search early. In this article, we describe three cases of GVHD after SOT, outline our approach to diagnosis and management, and then provide analysis of the three instructive cases.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHydroxyurea is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa.\r\nHydroxyurea at MTD is associated with lower malaria incidence in SCA through incompletely defined mechanisms, but treatment-associated mild myelosuppression with ANC < 3.0 x 109/L is salutary. Splenomegaly represents an unexplained risk factor for malaria infections among children with SCA in Africa.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIntegrating Novel Agents into the Treatment of Advanced Mycosis Fungoides and SÃ©zary Syndrome.\r\nTo gain the full benefit of these novel agents, we must develop strategies to match treatments to the patients most likely to benefit from them. Here, we consider both the current approaches to treatment selection based on clinical features and the future of molecular biomarker-guided therapy for patients with this heterogeneous disease.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNovel variants in GALE cause syndromic macrothrombocytopenia by disrupting glycosylation and thrombopoiesis. \r\nAltered distribution of filamin A and actin and delocalization of the von Willebrand Factor were also demonstrated. Overall, this study expands our knowledge of GALE-related thrombocytopenia and emphasized the critical role of GALE in the physiological glycosylation of key proteins involved in platelet production and function.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSecreted Mutant Calreticulins As Rogue Cytokines in Myeloproliferative Neoplasms.\r\nThus, secreted mutant CALR proteins will act more specifically on the MPN clone. In conclusion, a chaperone, CALR, can turn into a rogue cytokine through somatic mutation of its encoding gene.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.\r\nLO-CHOP demonstrates high efficacy and tolerability in newly diagnosed DLBCL, leading to a high rate of undetectable minimal residual disease by ctDNA by end of therapy. This trial is registered at as NCT02529852.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nApplying CRISPR-Cas9 screens to dissect hematological malignancies.\r\nSpecifically, within blood cancers, current CRISPR screens have specifically focused on improving our understanding of drug resistance strategies, disease biology, development of novel therapeutic approaches, and identifying the molecular mechanisms of current therapies, with an underlying aim of improving disease outcomes. Here, we review the development of CRISPR-Cas9 genome editing strategy, explicitly focusing on the recent advances in the CRISPR-Cas9 based screening approaches, its current capabilities, limitations, and future applications in the context of hematological malignancies.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCarfilzomib Combined with Rituximab, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory DLBCL.\r\nC-R-ICE is well tolerated in pts with R/R DLBCL with toxicities comparable to R-ICE therapy. Our data show that pts with non-GCB DLBCL benefit significantly from incorporating CFZ into second-line therapy and HDC-ASCT.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCNL and aCML should be considered as single entity based on molecular profiles and outcomes.\r\nWe identified four high-risk mutated genes, specifically CEBPA (ÃŸ=2.26, HR=9.54, p=0.003), EZH2 (ÃŸ=1.12, HR=3.062, p=0.009), NRAS (ÃŸ=1.29, HR=3.63, p=0.048) and U2AF1 (ÃŸ=1.75, HR=5.74, p=0.013) by multivariate analysis. Our findings underscore the relevance of molecular-risk classification in CNL/aCML as well as the importance of CSF3R mutations in these diseases.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEfficacy, Safety, and Molecular Response Predictors of Oral Ixazomib and Short-Course Rituximab in Untreated iNHL.\r\nIxazomib demonstrated efficacy alone and with short course rituximab in untreated iNHL while exhibiting favorable toxicity, convenience, and retention of B-cell immune response. This trial is registered at as NCT02339922.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHistone Deacetylase-6 Modulates the Effects of 4oC Platelets on Vascular Endothelial Permeability.\r\nIn addition, angiopoietin-2 (Ang-2), an inducer of vascular leak and antagonist of Ang-1, inhibited PLT barrier protection, suggesting involvement of the Tie-2 pathway. This study demonstrates that HDAC-6 inhibition with tubacin attenuates the diminished vasculo-protective properties of 4oC PLTs, and these properties may be independent of PLT circulation time.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLow toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy.\r\nOur findings suggest that, in patients with R/R DLBCL who have an indication for CAR T-cell therapy, treating patients in complete remission at time of infusion is feasible, safe, and associated with favorable disease control. Further exploration in a larger clinical trial setting is warranted.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPharmacokinetics, pharmacodynamics, safety and efficacy of crizanlizumab in patients with sickle cell disease.\r\nResults here demonstrate the PK/PD properties of crizanlizumab in SCD patients, and the potential sustained efficacy and long-term safety of the drug after >12 months' treatment. This trial is registered at as NCT03264989.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSafety and Immunogenicity of V114, a 15-valent Pneumococcal Conjugate Vaccine, in Children with Sickle Cell Disease (PNEU-SICKLE).\r\nTrial Registration: ClinicalTrials. gov: NCT03731182;  EudraCT: 2018-001152-35.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTargeting platelet GPVI with glenzocimab: a novel mechanism for inhibition.\r\nGlenzocimab did not bind to a truncated GPVI missing loop residues 129-136, thus validating the epitope identified in the crystal structure. Overall, these findings demonstrate that the binding of glenzocimab to the D2 domain of GPVI induces steric hindrance and structural modifications that drive the inhibition of GPVI interactions with its major ligands.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML.\r\nMechanistically, stimulation of C3AR-expressing cells with C3a, the ligand of C3AR, leads to activation of ERK1/2 and increased survival of AML cells, suggesting that this is an important signaling axis in this subtype of AML. Finally, we show that antibodies directed against C3AR efficiently elicit NK cell-mediated killing of primary AML cells ex vivo, highlighting C3AR as a candidate therapeutic target in NPM1-mutated AML.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nUnderweight children over 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.\r\nUnderweight participants (weight-for-age z-score < -1) had a greater probability of death during follow-up than those not underweight (p=0.043). Underweight status in school-aged children with sickle cell anemia is a previously unrecognized risk factor for early mortality in Nigeria and can be easily applied to screen children at risk for death.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS).\r\nMDS patients who achieve a CRh response had similar survival and duration on therapy as patients who achieve CR response and superior to other IWG responses. These data support further evaluation of CRh into future response criteria and clinical trials.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHaematologica\r\n    Allogeneic, Off-the-Shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high risk patients.\r\nIn conclusion, this study establishes the feasibility of preparing and delivering off-the-shelf SARS-CoV-2-directed VSTs to patients with COVID-19 and supports the clinical use of VSTs outside of the profoundly immune compromised setting (ClinicalTrials. gov number, NCT04401410).\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAnimal models of Diamond-Blackfan anemia: updates and challenges.\r\nIn the past decades, researchers have made significant progress in understanding the pathogenesis of DBA, but it remains unclear how the ubiquitous RP haploinsufficiency causes the erythroid-specific defect in hematopoiesis in DBA patients, and why there is a difference in penetrance and spontaneous remission among individuals who carry identical mutations. In this paper, we provide a comprehensive review of the development of DBA animal models and discuss the future research directions for these important experimental systems.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAxicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nClinical response to dabrafenib and chemotherapy in clonally-related histiocytosis and acute lymphoblastic leukemia.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nClonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nContribution of fetal microchimeric cells to maternal wound healing in sickle cell ulcers.\r\nIn a retrospective cohort of SCD patients, we demonstrated using several parameters that ever parous SCD women had a decreased burden related to leg ulcers compared to nulliparous women. Taken together, these results indicate that healing capacities of FMC are maintained long after delivery and may be targeted to promote wound healing in post-partum SCD patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDiffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL).\r\nClinical characteristics were similar between LO and EO, but LO more frequently received palliation (50% vs 23%: P=0.001) and had worse 2-year overall survival (OS) (48% vs 63%: P=0.001) and 2-year progression-free survival (PFS) (43% vs 56%: P=0.01). Patients receiving anthracycline did better than patients receiving palliation (P.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDisrupting autophagy in FLT3-mutant AML.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDysfunctional subsets of CD39+ T cells, distinct from PD-1+, driven by leukemic extracellular vesicles in myeloid leukemias.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHow different are blood platelets from women or men, young or elderly people?\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLongitudinal analysis of the evolution of cellular immunity to SARS-CoV-2 induced by infection and vaccination.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMonoclonal gammopathy of increasing significance: time to screen?\r\nWe review the literature and case for MG screening in this paper. In particular, we highlight areas that require focus to establish screening for MG.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPrevention and management of secondary central nervous system lymphoma.\r\nIn this review we focus on the identification of high-risk patients, prophylaxis strategies and recent treatment approaches for SCNSL. The incorporation of novel agents to immunochemotherapy deserves further study in prospective trials.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies.\r\ncRIT with 131 I-omburtamab is safe, has favorable dosimetry and may have a therapeutic benefit as adjuvant therapy for B7-H3-expressing leptomeningeal metastases.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.\r\nThe results of this phase 1 study provide rationale for the continued evaluation of olutasidenib in multiple patient populations with myeloid malignancies. Funding Forma Therapeutics.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Genetic deletion and pharmacologic inhibition of E3 ubiquitin ligase HOIP impairs the propagation of myeloid leukemia.\r\nFinally, the administration of thiolutin, which inhibits the catalytic activity of Hoip, improved the survival of recipients in murine myeloid leukemia and suppressed propagation in the patient-derived xenograft model of myeloid leukemia. Collectively, these data indicate that inhibition of LUBAC activity may be a valid therapeutic target for myeloid leukemia.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.\r\nMultivariate analyses for prognostic factors associated with OS identified female gender (HR 1.61), adverse cytogenetic risk (HR 2.52), and allogenic HSCT after gilteritinib (HR 0.13). Although these patients were more heavily pretreated, these real-world data reproduce the results of ADMIRAL and provide new insights into the course of patients previously treated by intensive chemotherapy and midostaurin and beyond the 2nd line of treatment who can benefit from treatment in an outpatient setting.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nInhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma.\r\nMoreover, pimozide showed a synergetic effect with etoposide, a chemotherapy drug, in cell and mouse models of rituximab/chemotherapy resistant DLBCL. Our study highlights the critical role of USP1 in the rituximab/chemotherapy resistance of DLBCL through deubiquitylating MAX, and provides a novel therapeutic strategy for rituximab/chemotherapy resistant DLBCL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nmTOR inhibition amplifies the anti-lymphoma effect of PI3KÃŸ/d blockage in diffuse large B-cell lymphoma.\r\nCollectively, our study reveals that subsets of DLBCLs are addicted to PI3KÃŸ/d signaling and thus identifies a previously unappreciated role of the PI3KÃŸ isoform in DLBCL survival. Furthermore, our data demonstrate that combined targeting of PI3KÃŸ/d and mTOR is effective in al major DLBCL subtypes supporting the evaluation of this strategy in a clinical trial setting.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPreclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.\r\nThe selective BCL-2 inhibitor, venetoclax, exhibited in vitro additivity in combination with hypomethylating or conventional chemotherapeutic agents. The addition of venetoclax to azacitidine resulted in a significant in vivo survival advantage indicating the therapeutic potential of this combination to improve outcome for infants with KMT2A-rearranged ALL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nVIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia.\r\nFinally, immune competent mice engrafted with CLL-like cells of EÂµ-MTCP1 over-expressing mice and treated with VIP152 demonstrated reduced disease burden and improvement in overall survival compared to vehicle-treated mice. These data suggest that VIP152 is a highly selective inhibitor of CDK9 that represents an attractive new therapy for CLL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThromb Haemost\r\n    Assessment of DOAC in GEriatrics (ADAGE study): rivaroxaban/apixaban concentrations and thrombin generation profiles in NVAF very elderly patients. \r\nOur study provides original data in very elderly patients receiving DOAC in real-life setting, showing great inter-individual variability in plasma concentrations and TG parameters. Further research is needed to understand the potential clinical impact of these findings.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGenetic predisposition of both waist circumference and hip circumference increased the risk of venous thromboembolism.\r\n There is a significant causal relationship between WC/HC and VTE/PE, which is consistent with observational studies. Taking measures to reduce WC/HC of obesity may help reduce the incidence of VTE/PE.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nObesity and the Risk of Venous Thromboembolism after Major Lower Limb Orthopaedic Surgery: A Literature Review.\r\nHence any increase in dosage may require intensive surveillance for the residual anticoagulant effects and careful balancing of risks and benefits on an individual basis. Our review discusses the basis for increased thrombotic risk in obesity, the evidence supporting dosage recommendations, and the implications of the current guidelines for pharmacological thromboprophylaxis in patients with obesity undergoing lower limb arthroplasty.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nReviews&Editorials\r\nPlenty of the editorials are available as full text through the publisher website using the provided link\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#vmcqzynnjx .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#vmcqzynnjx .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#vmcqzynnjx .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#vmcqzynnjx .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#vmcqzynnjx .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#vmcqzynnjx .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#vmcqzynnjx .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#vmcqzynnjx .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#vmcqzynnjx .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#vmcqzynnjx .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#vmcqzynnjx .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#vmcqzynnjx .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#vmcqzynnjx .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#vmcqzynnjx .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#vmcqzynnjx .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#vmcqzynnjx .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#vmcqzynnjx .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#vmcqzynnjx .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#vmcqzynnjx .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#vmcqzynnjx .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#vmcqzynnjx .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#vmcqzynnjx .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#vmcqzynnjx .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#vmcqzynnjx .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#vmcqzynnjx .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#vmcqzynnjx .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#vmcqzynnjx .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#vmcqzynnjx .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#vmcqzynnjx .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#vmcqzynnjx .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#vmcqzynnjx .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#vmcqzynnjx .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#vmcqzynnjx .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#vmcqzynnjx .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#vmcqzynnjx .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Venetoclax and hypomethylating agent therapy in myelodysplastic syndromes: big picture perspective.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    A challenging choice: consolidation in Ph+ ALL. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAML gets upSET when its dietary needs are unMet.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCardiotoxicity in patients treated with acalabrutinib. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGiving alloHSCT a needed LIF(t).\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMechanisms of resistance toÂ venetoclax. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nProtecting the fetus from FNAIT. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRBC, heal thyself: PK activators in SCD.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTransferrin-induced thrombosis in hypoxia.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nMiscellaneous\r\nmisc publications eg case reports, tools of the trade, images of the month, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#ddjdnnblcp .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#ddjdnnblcp .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#ddjdnnblcp .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#ddjdnnblcp .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#ddjdnnblcp .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#ddjdnnblcp .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#ddjdnnblcp .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#ddjdnnblcp .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#ddjdnnblcp .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#ddjdnnblcp .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#ddjdnnblcp .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#ddjdnnblcp .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#ddjdnnblcp .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#ddjdnnblcp .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#ddjdnnblcp .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#ddjdnnblcp .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#ddjdnnblcp .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#ddjdnnblcp .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#ddjdnnblcp .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#ddjdnnblcp .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#ddjdnnblcp .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#ddjdnnblcp .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#ddjdnnblcp .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#ddjdnnblcp .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#ddjdnnblcp .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#ddjdnnblcp .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#ddjdnnblcp .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#ddjdnnblcp .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#ddjdnnblcp .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#ddjdnnblcp .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#ddjdnnblcp .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#ddjdnnblcp .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#ddjdnnblcp .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#ddjdnnblcp .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#ddjdnnblcp .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Blood\r\n    Allogeneic HCT for Ph+ ALL in CR1 with CMR. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlast phagocytosis. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPlatelet satellitism in immune thrombocytopenic purpura.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRisks of therapy-related hematologic neoplasms beyond myelodysplastic syndromes and acute myeloid leukemia.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    Abramson JS, Siddiqi T, Garcia J, etÂ al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6):1695-1705.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nChari A, Cho HJ, Dhadwal A, etÂ al. A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood Adv. 2017;1(19):1575-1583.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCuring CLL: one clone at a time.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMegakaryocyte buds are distinct from microvesicles and likely to represent platelet precursors.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSevere Autoimmune intravascular hemolytic anemia in patients receiving Alemtuzumab for Multiple sclerosis.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSmith CC, Levis MJ, Perl AE, etÂ al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCA Cancer J Clin\r\n    Multidisciplinary considerations in the maintenance treatment of poly(ADP-ribose) polymerase inhibitors for homologous recombination-proficient, advanced-stage epithelial ovarian cancer.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHaematologica\r\n    Identification of multiple genetic loci associated with RBC alloimmunization in mice.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Frequency and prognostic implications of KMT2A rearrangements in children with precursor B-cell lymphoma.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nLetters&Replies\r\nLetters to the editors and authorsâ€™ replies\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#xzylcmvjkf .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#xzylcmvjkf .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#xzylcmvjkf .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#xzylcmvjkf .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#xzylcmvjkf .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#xzylcmvjkf .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#xzylcmvjkf .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#xzylcmvjkf .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#xzylcmvjkf .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#xzylcmvjkf .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#xzylcmvjkf .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#xzylcmvjkf .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#xzylcmvjkf .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#xzylcmvjkf .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#xzylcmvjkf .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#xzylcmvjkf .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#xzylcmvjkf .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#xzylcmvjkf .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#xzylcmvjkf .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#xzylcmvjkf .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#xzylcmvjkf .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#xzylcmvjkf .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#xzylcmvjkf .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#xzylcmvjkf .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#xzylcmvjkf .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#xzylcmvjkf .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#xzylcmvjkf .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#xzylcmvjkf .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#xzylcmvjkf .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#xzylcmvjkf .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#xzylcmvjkf .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#xzylcmvjkf .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#xzylcmvjkf .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#xzylcmvjkf .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#xzylcmvjkf .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    SARS-CoV-2 mRNA vaccination of aplastic anemia patients is safe and effective.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    Breakthrough infections in MPN-COVID vaccinated patients.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCharacteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIn response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIncreased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia.\r\nIn an adoptive transfer CLL mouse model, mice treated with nemtabrutinib and venetoclax had prolonged survival compared to mice treated with ibrutinib and venetoclax. Our preclinical studies further validate the combination of BTK inhibitors with venetoclax and justify further investigation of combining nemtabrutinib with venetoclax in CLL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSIRPa-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPa signal pathway via blocking the \"don't eat me\" signal and activating the \"eat me\" signal.\r\nFinally, IMM01 demonstrated a favorable safety profile with no human RBC binding activity or hemagglutination induction. IMM01 inhibits the growth of tumor cells by the following three possible mechanisms: (1) directly activating macrophages to phagocytize tumor cells;  (2) activated macrophages degrade phagocytized tumor cells and present tumor antigens to T cells through MHC molecules to activate T cells;  (3) activated macrophages can convert \"cold tumors\" into \"hot tumors\" and increase the infiltration of immune cells through chemotaxis by secreting some cytokines and chemokines.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nShould we give oligomonocytic chronic myelomonocytic leukemia a higher prominence in the next WHO Classification of Haematolymphoid Tumors?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n// add bootstrap table styles to pandoc tables\r\nfunction bootstrapStylePandocTables() {\r\n  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');\r\n}\r\n$(document).ready(function () {\r\n  bootstrapStylePandocTables();\r\n});\r\n\r\n\r\n\r\n$(document).ready(function () {\r\n  window.buildTabsets(\"TOC\");\r\n});\r\n\r\n$(document).ready(function () {\r\n  $('.tabset-dropdown > .nav-tabs > li').click(function () {\r\n    $(this).parent().toggleClass('nav-tabs-open');\r\n  });\r\n});\r\n\r\n  (function () {\r\n    var script = document.createElement(\"script\");\r\n    script.type = \"text/javascript\";\r\n    script.src  = \"https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML\";\r\n    document.getElementsByTagName(\"head\")[0].appendChild(script);\r\n  })();\r\n\r\n\r\n\r\n\r\n\r\n",
    "preview": {},
    "last_modified": "2022-11-18T13:07:16-05:00",
    "input_file": {}
  },
  {
    "path": "hema/11-11-2022/",
    "title": "Fri Nov 11 2022",
    "description": "73 articles - From Friday Nov 04 2022 to Friday Nov 11 2022",
    "author": [],
    "date": "2022-11-11",
    "categories": [],
    "contents": "\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nparm_toc.knith1 {font-size: 34px;}\r\n       h1.title {font-size: 38px;}\r\n       h2 {font-size: 30px;}\r\n       h3 {font-size: 24px;}\r\n       h4 {font-size: 18px;}\r\n       h5 {font-size: 16px;}\r\n       h6 {font-size: 12px;}\r\n       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}\r\n       pre:not([class]) { background-color: white }\r\n  code{white-space: pre-wrap;}\r\n  span.smallcaps{font-variant: small-caps;}\r\n  span.underline{text-decoration: underline;}\r\n  div.column{display: inline-block; vertical-align: top; width: 50%;}\r\n  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}\r\n  ul.task-list{list-style: none;}\r\n    code{white-space: pre;}\r\nif (window.hljs) {\r\n  hljs.configure({languages: []});\r\n  hljs.initHighlightingOnLoad();\r\n  if (document.readyState && document.readyState === \"complete\") {\r\n    window.setTimeout(function() { hljs.initHighlighting(); }, 0);\r\n  }\r\n}\r\n\r\n.main-container {\r\n  max-width: 940px;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n}\r\nimg {\r\n  max-width:100%;\r\n}\r\n.tabbed-pane {\r\n  padding-top: 12px;\r\n}\r\n.html-widget {\r\n  margin-bottom: 20px;\r\n}\r\nbutton.code-folding-btn:focus {\r\n  outline: none;\r\n}\r\nsummary {\r\n  display: list-item;\r\n}\r\npre code {\r\n  padding: 0;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs {\r\n  display: inline-table;\r\n  max-height: 500px;\r\n  min-height: 44px;\r\n  overflow-y: auto;\r\n  border: 1px solid #ddd;\r\n  border-radius: 4px;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {\r\n  content: \"<U+E258>\";\r\n  border: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active {\r\n  display: block;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li > a,\r\n.tabset-dropdown > .nav-tabs > li > a:focus,\r\n.tabset-dropdown > .nav-tabs > li > a:hover {\r\n  border: none;\r\n  display: inline-block;\r\n  border-radius: 4px;\r\n  background-color: transparent;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li {\r\n  display: block;\r\n  float: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li {\r\n  display: none;\r\n}\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nGuidelines\r\nMeta-analysis\r\nOriginal articles\r\nReviews&Editorials\r\nMiscellaneous\r\nLetters&Replies\r\n\r\n\r\n\r\n$(function () {\r\n          $('#goTop').goTop({\"container\":\"\",\"appear\":200,\"scrolltime\":800,\"src\":\"fas fa-chevron-up\",\"width\":45,\"place\":\"left\",\"color\":\"\",\"fadein\":500,\"fadeout\":500,\"opacity\":0.5,\"marginX\":2,\"marginY\":2,\"zIndex\":9});\r\n         });\r\nGuidelines\r\nGuidelines and related publications, position statements, white papers, technical reviews, consensus statements, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#ahcvjoybwi .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#ahcvjoybwi .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#ahcvjoybwi .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#ahcvjoybwi .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#ahcvjoybwi .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#ahcvjoybwi .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#ahcvjoybwi .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#ahcvjoybwi .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#ahcvjoybwi .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#ahcvjoybwi .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#ahcvjoybwi .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#ahcvjoybwi .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#ahcvjoybwi .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#ahcvjoybwi .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#ahcvjoybwi .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#ahcvjoybwi .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#ahcvjoybwi .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#ahcvjoybwi .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#ahcvjoybwi .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#ahcvjoybwi .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#ahcvjoybwi .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#ahcvjoybwi .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#ahcvjoybwi .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#ahcvjoybwi .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#ahcvjoybwi .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#ahcvjoybwi .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#ahcvjoybwi .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#ahcvjoybwi .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#ahcvjoybwi .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#ahcvjoybwi .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#ahcvjoybwi .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#ahcvjoybwi .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#ahcvjoybwi .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#ahcvjoybwi .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#ahcvjoybwi .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    \r\n\r\n\r\nMeta-analysis\r\nmeta-analyses and systematic reviews\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#qpiecvqhzo .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#qpiecvqhzo .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#qpiecvqhzo .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#qpiecvqhzo .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#qpiecvqhzo .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#qpiecvqhzo .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#qpiecvqhzo .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#qpiecvqhzo .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#qpiecvqhzo .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#qpiecvqhzo .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#qpiecvqhzo .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#qpiecvqhzo .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#qpiecvqhzo .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#qpiecvqhzo .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#qpiecvqhzo .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#qpiecvqhzo .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#qpiecvqhzo .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#qpiecvqhzo .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#qpiecvqhzo .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#qpiecvqhzo .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#qpiecvqhzo .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#qpiecvqhzo .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#qpiecvqhzo .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#qpiecvqhzo .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#qpiecvqhzo .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#qpiecvqhzo .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#qpiecvqhzo .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#qpiecvqhzo .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#qpiecvqhzo .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#qpiecvqhzo .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#qpiecvqhzo .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#qpiecvqhzo .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#qpiecvqhzo .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#qpiecvqhzo .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#qpiecvqhzo .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Lancet Haematol\r\n    Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis.\r\nFurther investigations are needed to improve understanding on why lenalidomide only promotes SPM in patients with multiple myeloma. Funding None.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThromb Haemost\r\n    Mortality of Escalation and Modulation Antithrombotic Therapy in Coronary Artery Disease Patients: A Meta-analysis of Randomized Controlled Trials.\r\n Either escalation or modulation of ATT has little benefit in all-cause mortality. The variability of the treatment effects on all-cause mortality was mainly attributed to the variability of major or minor bleeding, but not to MI.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nOriginal articles\r\nRCT, clinical trials, retrospective studies, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#lgxtvulyub .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#lgxtvulyub .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lgxtvulyub .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#lgxtvulyub .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#lgxtvulyub .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#lgxtvulyub .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lgxtvulyub .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#lgxtvulyub .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#lgxtvulyub .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#lgxtvulyub .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#lgxtvulyub .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#lgxtvulyub .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#lgxtvulyub .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#lgxtvulyub .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#lgxtvulyub .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#lgxtvulyub .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#lgxtvulyub .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#lgxtvulyub .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#lgxtvulyub .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#lgxtvulyub .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#lgxtvulyub .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#lgxtvulyub .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#lgxtvulyub .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#lgxtvulyub .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lgxtvulyub .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#lgxtvulyub .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lgxtvulyub .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#lgxtvulyub .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#lgxtvulyub .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#lgxtvulyub .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#lgxtvulyub .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#lgxtvulyub .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#lgxtvulyub .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#lgxtvulyub .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#lgxtvulyub .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival.\r\nThis survival advantage was also noted in transfusion-dependent patients (3.7 vs 1.9years;  p=0.01;  HR 0.3) and appeared to be restricted to patients with unfavorable genetic profile. The current study suggests short-term survival benefit associated with anemia response in momelotinib treated patients with MF.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy.\r\nA large proportion of post-ALL lymphoid neoplasms are associated with an immunodeficient state, likely precipitated by ALL maintenance therapy. Awareness of this underrecognized entity and pertinent diagnostic tests are crucial for early diagnosis and optimal therapy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGenetic basis and molecular profiling in myeloproliferative neoplasms.\r\nFactors that control the conversion from clonal hematopoiesis to MPN include inherited predisposition, presence of additional mutations and inflammation. The complete knowledge of the mutational landscape in individual MPN patients is now increasingly being used to predict outcome and chose the optimal therapy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHow I treat thrombotic microangiopathy in the era of rapid genomics.\r\nBy taking precedence over a phenotypic approach, an unbiased genomic-focused analysis maximizes the chances of discovering new descriptions related to a given variant. Presented here are four cases of TMA which highlight these issues and substantiate the promise of fast-track genomic sequencing.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImpact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy.\r\nInvestigation of multicenter outcomes and access disparities outside of clinical-trial settings is warranted. Clinical trials: NCT01626495;  NCT02435849 ;  NCT02374333;  NCT02228096;  NCT02906371.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLentiviral Gene Therapy for X-Linked Chronic Granulomatous Disease Recapitulates Endogenous CYBB Regulation and Expression.\r\ncepacia infection, and restored healthy donor levels of anti-microbial oxidase activity in neutrophils derived from X-CGD patient HSPCs. Our findings validate the bioinformatics-guided design approach and have yielded a novel lentiviral vector with clinical promise for the treatment of X-CGD.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLiver sinusoidal endothelial cells induce BMP6 expression in response to non-transferrin bound iron.\r\nOur data suggest that during systemic iron overload, LSECs internalize NTBI, which promotes oxidative stress and thereby transcriptionally induces Bmp6 via Nrf2. Tfr1 appears to contribute to iron sensing by LSECs mostly under low iron conditions.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNatural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy.\r\nBoth unmodified NKTs, which specifically recognize CD1d-bound glycolipid antigens expressed by some types of tumors, and CAR-redirected NKTs are in development as the next generation of allogeneic cell therapy products. In this review, we describe studies on the biology of NKTs and other types of innate-like T cells and summarize experiences in the clinic with unmodified and CAR-redirected NKTs, including recent interim reports on allogeneic NKTs.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRetinoid X receptor promotes hematopoietic stem cell fitness and quiescence and preserves hematopoietic homeostasis.\r\nFitness loss and associated RNA transcriptome and splicing alterations in RXRa; RXRb-deficient HSCs are prevented by Myc haploinsufficiency. Our study reveals the critical importance of RXRs for the maintenance of HSC fitness and their protection from premature aging.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR-T cell immunotherapy.\r\nThese data support an ongoing phase I clinical trial of combined CD19 CAR-T and NKTR-255 for R/R B-cell malignancies. This trial is registered at as NCT01865617.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nApplying CRISPR-Cas9 screens to dissect hematological malignancies.\r\nSpecifically, within blood cancers, current CRISPR screens have specifically focused on improving our understanding of drug resistance strategies, disease biology, development of novel therapeutic approaches, and identifying the molecular mechanisms of current therapies, with an underlying aim of improving disease outcomes. Here, we review the development of CRISPR-Cas9 genome editing strategy, explicitly focusing on the recent advances in the CRISPR-Cas9 based screening approaches, its current capabilities, limitations, and future applications in the context of hematological malignancies.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Adults with Relapsed or Refractory Follicular Lymphoma.\r\nUnder current pricing, CAR-T is unlikely to be cost-effective in unselected FL patients in the third-line setting. Both randomized clinical trials and longer-term clinical follow up can help clarify the benefits of CAR-T and optimal sequencing in patients with FL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCreating an Automated Contemporaneous Cohort in Sickle Cell Anemia to Predict Survival After Disease-Modifying Therapy.\r\nCompared to those receiving no disease-modifying treatment, those treated with hydroxyurea therapy had significantly lower hazard of mortality (hazard ratio=0.38, p=0.016), but no statistical difference for those receiving regular blood transfusions compared to no disease-modifying therapy (hazard ratio=0.71, p=0.440). An automated contemporaneous SCA cohort can be generated to estimate mortality in children and adults with SCA.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDownregulated KLF2 in polycythemia vera and essential thrombocythemia induces prothrombotic gene expression.\r\nIn PV and ET patients, KLF2 expression was induced by pegylated interferon-a (PegINFa) but not by hydroxyurea treatments. These data suggest that KLF2 may be a regulator of PV and ET thrombosis and a novel therapeutic target to prevent thrombosis.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGata1s mutant mice display persistent defects in the erythroid lineage.\r\nHere we demonstrate that Gata1s mutant mice display macrocytic anemia and features of aberrant megakaryopoiesis throughout life, culminating in profound splenomegaly and bone marrow fibrosis. These data support the use of this animal model for studies of GATA1 deficiencies.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHypodiploidy has Unfavorable Impact on Survival in Pediatric Acute Myeloid Leukemia:An I-BFM Study Group collaboration.\r\nAllogeneic stem cell transplantation (SCT) in first complete remission (CR1) (n=18) did not mitigate the unfavorable outcome of hypodiploidy (adjusted HR for OS was 1.5, p=0.42). We identified pediatric hypodiploid AML as a rare subgroup with an inferior prognosis even in patients treated with SCT in CR1.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLow toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy.\r\nOur findings suggest that, in patients with R/R DLBCL who have an indication for CAR T-cell therapy, treating patients in complete remission at time of infusion is feasible, safe, and associated with favorable disease control. Further exploration in a larger clinical trial setting is warranted.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nOutcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe.\r\nIn conclusion, despite their poor outcomes, SNs that occur after UCBT are extremely rare. Identification of associated risk factors and early detection may help to improve OS.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPharmacokinetics, pharmacodynamics, safety and efficacy of crizanlizumab in patients with sickle cell disease.\r\nResults here demonstrate the PK/PD properties of crizanlizumab in SCD patients, and the potential sustained efficacy and long-term safety of the drug after >12 months' treatment. This trial is registered at as NCT03264989.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nProspective changes of pancreatic iron in patients with thalassemia major and association with chelation therapy.\r\nThe reduction in pancreatic iron levels was comparable among the three groups. Our data showed that it is difficult to remove the iron from the pancreas and that the three iron chelators in monotherapy have a comparable efficacy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nReg3a levels at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use.\r\nReg3a, a known biomarker of acute GI GvHD correlates with intestinal dysbiosis induced by early antibiotic treatment in the period of pretransplant conditioning. Serum concentrations of Reg3a measured on the day of graft infusion are predictive of the risk for TRM of allogenic SCT recipients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients.\r\nIn both risk groups, the two periods were comparable for CMV disease, overall survival, progression-free survival, relapse, and non-relapse mortality. We concluded that a risk-based strategy for letermovir use is an effective strategy which maintains the high efficacy of letermovir in high-risk patients but allows some low-risk patients not to use letermovir.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nWaldenstrÃ¶m Macroglobulinemia Whole Genome Reveals Prolonged Germinal Center Activity and Late Copy Number Aberrations.\r\nIn summary, WGS analysis in WM allows the demonstration of sustained germinal center activity over time and allows the reconstruction of the temporal evolution of specific genomic features. In addition, our data suggests that, while MYD88-mutations are central to WM clone establishment and can be observed in precursor disease, CNA may contribute to later phases, and may be used as a biomarker for progression risk from precursor conditions to symptomatic disease.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms.\r\nThe discovery that p300-dependent acetylation regulates GATA-3 mediated transcription by attenuating DNA binding has novel therapeutic implications. As most patients afflicted with GATA-3 driven T-cell neoplasms will succumb to their disease within a few years of diagnosis, these findings suggest opportunities to improve outcomes for these patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nThe PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy.\r\nThe minimal effects of THZ-P1-2 observed in healthy CD34 + cells suggest a favorable therapeutic window. Our study provides insights into the pharmacological inhibition of PIP4K2s targeting mitochondrial homeostasis and autophagy, shedding light on a new class of drugs for acute leukemia.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis.\r\nDecreased RIG-I in HcPCs promotes necroinflammation-induced hepatocarcinogenesis, while increased constitutive methylated RIG-I enhances steatosis and NASH-induced hepatocarcinogenesis. JMJD4-demethylated RIG-I prevents both necroinflammation and NASH-induced hepatocarcinogenesis, which provides mechanistic insight and potential target for preventing HCC.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nSafe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia.\r\nOur data indicate the feasibility of an innovative off-the-shelf therapeutic strategy based on CAR.CD123-NK cells, characterized by remarkable efficacy and an improved safety profile compared to CAR.CD123-T cells. These findings open a novel intriguing scenario not only for the treatment of refractory/resistant AML patients but also to further investigate the use of CAR-NK cells in other cancers characterized by highly difficult targeting with the most conventional T effector cells.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nLancet Haematol\r\n    Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.\r\nInterpretation Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone for induction therapy improved rates of MRD negativity with no new safety signals in patients with newly diagnosed transplantation-eligible multiple myeloma. Funding Sanofi and Bristol Myers Squibb (Celgene).\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Genetic deletion and pharmacologic inhibition of E3 ubiquitin ligase HOIP impairs the propagation of myeloid leukemia.\r\nFinally, the administration of thiolutin, which inhibits the catalytic activity of Hoip, improved the survival of recipients in murine myeloid leukemia and suppressed propagation in the patient-derived xenograft model of myeloid leukemia. Collectively, these data indicate that inhibition of LUBAC activity may be a valid therapeutic target for myeloid leukemia.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIdentification and interrogation of the gene regulatory network of CEBPA-double mutant acute myeloid leukemia.\r\nWe identify the binding sites of mutated C/EBPa proteins in primary cells, we show that C/EBPa, AP-1 factors and RUNX1 colocalize and are required for AML maintenance, and we employ single cell experiments to link important network nodes to the specific differentiation trajectory from leukemic stem to blast cells. Taken together, our study provides an important resource which predicts the specific therapeutic vulnerabilities of this AML subtype in human cells.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIn vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance.\r\nAccordingly, venetoclax re-sensitized derivative tumors towards chemotherapy, despite genomic heterogeneity, demonstrating direct translatability of the approach. Hence, despite the presence of multiple resistance-associated genomic alterations, effective rescue treatment for polychemotherapy-resistant tumors can be identified using functional testing in preclinical models.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nInhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma.\r\nMoreover, pimozide showed a synergetic effect with etoposide, a chemotherapy drug, in cell and mouse models of rituximab/chemotherapy resistant DLBCL. Our study highlights the critical role of USP1 in the rituximab/chemotherapy resistance of DLBCL through deubiquitylating MAX, and provides a novel therapeutic strategy for rituximab/chemotherapy resistant DLBCL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLoss of bisecting GlcNAcylation on MCAM of bone marrow stoma determined pro-tumoral niche in MDS/AML.\r\nMCAM on stromal cell surface with reduced bisecting GlcNAc bound strongly to CD13 on myeloid cells, activated responding ERK signaling, and thereby promoted myeloid cell growth. Our findings, taken together, suggest a novel mechanism whereby MDS/AML clonal cells generate a self-permissive niche by modifying glycosylation level of stromal cells.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nmTOR inhibition amplifies the anti-lymphoma effect of PI3KÃŸ/d blockage in diffuse large B-cell lymphoma.\r\nCollectively, our study reveals that subsets of DLBCLs are addicted to PI3KÃŸ/d signaling and thus identifies a previously unappreciated role of the PI3KÃŸ isoform in DLBCL survival. Furthermore, our data demonstrate that combined targeting of PI3KÃŸ/d and mTOR is effective in al major DLBCL subtypes supporting the evaluation of this strategy in a clinical trial setting.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nOutcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma.\r\nThe presence of =2 of these factors was associated with inferior OS compared to =1 (56% vs 19%). In this largest analysis to date of patients who progressed or relapsed after CD19-CAR-T, survival is poor, though novel agents such as polatuzumab and lenalidomide may have hold promise.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nReviews&Editorials\r\nPlenty of the editorials are available as full text through the publisher website using the provided link\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#avhtpifgcs .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#avhtpifgcs .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#avhtpifgcs .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#avhtpifgcs .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#avhtpifgcs .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#avhtpifgcs .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#avhtpifgcs .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#avhtpifgcs .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#avhtpifgcs .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#avhtpifgcs .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#avhtpifgcs .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#avhtpifgcs .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#avhtpifgcs .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#avhtpifgcs .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#avhtpifgcs .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#avhtpifgcs .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#avhtpifgcs .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#avhtpifgcs .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#avhtpifgcs .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#avhtpifgcs .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#avhtpifgcs .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#avhtpifgcs .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#avhtpifgcs .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#avhtpifgcs .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#avhtpifgcs .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#avhtpifgcs .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#avhtpifgcs .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#avhtpifgcs .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#avhtpifgcs .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#avhtpifgcs .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#avhtpifgcs .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#avhtpifgcs .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#avhtpifgcs .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#avhtpifgcs .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#avhtpifgcs .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Ann Oncol\r\n    COP27 Climate Change Conference: urgent action needed for Africa and the world.\r\nIt is highly unjust that the most impacted nations have contributed the least to global cumulative emissions, which are driving the climate crisis and its increasingly severe effects. North America and Europe have contributed 62% of carbon dioxide emissions since the Industrial Revolution, whereas Africa has contributed only 3% (14).\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    AML gets upSET when its dietary needs are unMet.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGiving alloHSCT a needed LIF(t).\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRBC, heal thyself: PK activators in SCD.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTransferrin-induced thrombosis in hypoxia.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCA Cancer J Clin\r\n    Cancer statistics for American Indian and Alaska Native individuals, 2022: Including increasing disparities in early onset colorectal cancer.\r\nThese findings highlight the need for more effective strategies to reduce the prevalence of chronic oncogenic infections and improve access to high-quality cancer screening and treatment for AIAN individuals. Mitigating the disparate burden will require expanded financial support of tribal health care as well as increased collaboration and engagement with this marginalized population.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.\r\nAdditionally, the competitive landscape and business field is presented. This review offers a comprehensive overview of the effort driven by biotech and pharmaceutical companies and by academic centers to bring NK cell therapies to pivotal clinical trial stages and to market authorization.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    Iron deficiency anaemia-an ongoing challenge.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nMiscellaneous\r\nmisc publications eg case reports, tools of the trade, images of the month, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#apicasvlsu .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#apicasvlsu .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#apicasvlsu .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#apicasvlsu .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#apicasvlsu .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#apicasvlsu .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#apicasvlsu .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#apicasvlsu .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#apicasvlsu .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#apicasvlsu .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#apicasvlsu .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#apicasvlsu .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#apicasvlsu .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#apicasvlsu .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#apicasvlsu .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#apicasvlsu .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#apicasvlsu .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#apicasvlsu .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#apicasvlsu .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#apicasvlsu .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#apicasvlsu .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#apicasvlsu .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#apicasvlsu .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#apicasvlsu .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#apicasvlsu .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#apicasvlsu .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#apicasvlsu .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#apicasvlsu .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#apicasvlsu .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#apicasvlsu .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#apicasvlsu .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#apicasvlsu .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#apicasvlsu .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#apicasvlsu .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#apicasvlsu .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    CAR T cell-driven cerebrospinal fluid cytokine storm with confounding neurological picture in chemorefractory primary cardiac lymphoma.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nF9 mutations causing deletion beyond serine protease domain confer higher risk for inhibitor development in hemophilia B.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIpilimumab plus decitabine for patients with MDS or AML in post-transplant or transplant naÃ¯ve settings.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNeutrophil-specific depletion of gasdermin D does not protect against sepsis.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPlatelet satellitism in immune thrombocytopenic purpura.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nProgressive Multifocal Leukoencephalopathy in Patients Treated With Chimeric Antigen Receptor T-Cells.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    \"Cord Blood Power\" and \"What is Success after BMT\"?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBuettner R, Morales C, Caserta E, etÂ al. Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting. Blood Adv. 2019;3(7):1027-1032.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nChemical degradation of BTK/TEC as a novel approach to inhibit platelet function.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCuring CLL: one clone at a time.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMegakaryocyte buds are distinct from microvesicles and likely to represent platelet precursors.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCA Cancer J Clin\r\n    Colonoscopies for patients aged 45-49 years yield positive results.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSustained weight loss may reduce cancer risk.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    Burning out-whose responsibility is it?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIsolated IgG4-related disease of the left maxillary antrum.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMaximising response depth is important in multiple myeloma.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPlace-of-care manufacturing of gene therapies.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRahul Bhargava: making bone marrow transplantation accessible in India.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Discriminating activities of DEAD-Box Helicase 41 from myeloid malignancy-associated germline variants by genetic rescue.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nFrequency and prognostic implications of KMT2A rearrangements in children with precursor B-cell lymphoma.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHow T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThromb Haemost\r\n    Newborn and Pediatric Reference Intervals for Coagulation Assays Using Novel Reagents.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nLetters&Replies\r\nLetters to the editors and authorsâ€™ replies\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#vlrvohorus .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#vlrvohorus .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#vlrvohorus .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#vlrvohorus .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#vlrvohorus .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#vlrvohorus .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#vlrvohorus .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#vlrvohorus .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#vlrvohorus .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#vlrvohorus .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#vlrvohorus .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#vlrvohorus .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#vlrvohorus .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#vlrvohorus .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#vlrvohorus .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#vlrvohorus .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#vlrvohorus .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#vlrvohorus .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#vlrvohorus .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#vlrvohorus .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#vlrvohorus .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#vlrvohorus .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#vlrvohorus .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#vlrvohorus .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#vlrvohorus .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#vlrvohorus .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#vlrvohorus .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#vlrvohorus .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#vlrvohorus .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#vlrvohorus .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#vlrvohorus .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#vlrvohorus .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#vlrvohorus .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#vlrvohorus .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#vlrvohorus .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Efficacy of Front-line Ibrutinib versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. A Retrospective Multicenter \"Real-World\" Study.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nSurvival trends in hematological malignancies in the Nordic countries through 50 years.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nJ Hematol Oncol\r\n    FIT-based risk-stratification model effectively screens colorectal neoplasia and early-onset colorectal cancer in Chinese population: a nationwide multicenter prospective study.\r\nThe risk-stratification model identified 73.5% CN, 82.6% ACN, and 93.6% CRC when guiding 52.7% individuals to receive colonoscopy and identified 55.8% early-onset ACNs and 72.7% early-onset CRCs with only 25.6% young individuals receiving colonoscopy. The risk-stratification model showed a good risk-stratification ability for CN and early-onset CRCs in Chinese population, including individuals with NSGS and young age.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nLeukemia\r\n    Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n// add bootstrap table styles to pandoc tables\r\nfunction bootstrapStylePandocTables() {\r\n  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');\r\n}\r\n$(document).ready(function () {\r\n  bootstrapStylePandocTables();\r\n});\r\n\r\n\r\n\r\n$(document).ready(function () {\r\n  window.buildTabsets(\"TOC\");\r\n});\r\n\r\n$(document).ready(function () {\r\n  $('.tabset-dropdown > .nav-tabs > li').click(function () {\r\n    $(this).parent().toggleClass('nav-tabs-open');\r\n  });\r\n});\r\n\r\n  (function () {\r\n    var script = document.createElement(\"script\");\r\n    script.type = \"text/javascript\";\r\n    script.src  = \"https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML\";\r\n    document.getElementsByTagName(\"head\")[0].appendChild(script);\r\n  })();\r\n\r\n\r\n\r\n\r\n\r\n",
    "preview": {},
    "last_modified": "2022-11-11T19:39:22-05:00",
    "input_file": {}
  }
]
